公开(公告)号：AT510824T

公开(公告)日：2011-06-15

申请号：AT08166079

申请日：2004-06-10

Applicant: ABBOTT LAB

Inventor： GOMTSYAN ARTHUR ,  BAYBURT EROL ,  LEE CHIH-HUNG ,  KOENIG JOHN ,  SCHMIDT ROBERT ,  LUKIN KIRILL ,  CHAMBOURNIER GILLES ,  HSU MARGARET ,  LEANNA ROBERT ,  CINK RUSSEL

IPC: C07D217/02 ,  A61K31/416 ,  A61K31/472 ,  A61P13/10 ,  C07C211/42 ,  C07D231/56 ,  C07D401/12 ,  C07D403/12

Abstract: The present invention discloses novel compounds of general formula (I), or a pharmaceutically acceptable salt thereof (in which X 1 - X 5 , R 5 - R 8b , Z 1 - Z 2 and Ar 1 are defined herein), pharmaceutical compositions including those compounds and a process for making those compounds. The compounds of formula (I) are useful for treating pain, bladder overreactivity, urinary incontinence, inflammatory hyperalgesia by inhibiting the VR1 receptor in mammals.

公开(公告)号：CA2658896A1

公开(公告)日：2008-01-31

申请号：CA2658896

申请日：2007-07-24

Applicant: ABBOTT LAB

Inventor： VISWANATH SHEKHAR ,  BARTELT LARRY ,  ZHANG GEOFF ,  CHEN SHUANG ,  BORCHARDT THOMAS ,  LEANNA ROBERT ,  HENRY RODGER ,  DHAON MADHUP ,  RASMUSSEN MICHAEL

IPC: C07D498/18 ,  A61K31/395 ,  A61K31/4353 ,  A61P37/06

Abstract: A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate. The rapamycin analog can have a structure of Formula (I), which is optionally a prodrug, salt, derivative, or combination thereof: Formula (I)

公开(公告)号：DE69520368T2

公开(公告)日：2001-06-28

申请号：DE69520368

申请日：1995-11-15

Applicant: ABBOTT LAB

Inventor： LEANNA ROBERT ,  MORTON E

IPC: B01J31/02 ,  C07B61/00 ,  C07D277/24 ,  C07D277/32

Abstract: A process for the preparation of 5-hydroxymethylthiazole comprises reacting a compound of the formula, with a carboxylic acid salt (optimally in the presence of a quaternary ammonium salt) and hydrolyzing the resulting ester. Subsequent dechlorination gives 5-hydroxymethylthiazole.

公开(公告)号：BRPI0714945A2

公开(公告)日：2013-05-21

申请号：BRPI0714945

申请日：2007-07-24

Applicant: ABBOTT LAB

Inventor： VISWANATH SHEKHAR ,  BARTELT LARRY ,  LEANNA ROBERT ,  RASMUSSEN MICHAEL ,  DHAON MADHUP ,  HENRY RODGER ,  BORCHARDT THOMAS ,  CHEN SHUANG ,  ZHANG GEOFF

IPC: C07D498/18 ,  A61K31/395 ,  A61K31/4353 ,  A61P37/06

Abstract: A process for preparing a crystalline form of a rapamycin analog, which process comprises: combining the rapamycin analog with at least one organic medium to form a mixture that is saturated with the rapamycin analog; incubating the saturated mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog from the organic medium.

公开(公告)号：ZA200900740B

公开(公告)日：2010-05-26

申请号：ZA200900740

申请日：2007-07-24

Applicant: ABBOTT LAB

Inventor： VISWANATH SHEKHAR ,  BARTELT LARRY ,  LEANNA ROBERT ,  RASMUSSEN MICHAEL ,  DHAON MADHUP ,  HENRY RODGER ,  BORCHARDT THOMAS ,  CHEN SHUANG ,  ZHANG GEOFF

IPC: A61K20100101 ,  A61P20100101 ,  C07D20100101

公开(公告)号：MX2009001067A

公开(公告)日：2009-06-17

申请号：MX2009001067

申请日：2007-07-24

Applicant: ABBOTT LAB

Inventor： BORCHARDT THOMAS ,  HENRY RODGER ,  DHAON MADHUP ,  VISWANATH SHEKHAR ,  BARTELT LARRY ,  LEANNA ROBERT ,  RASMUSSEN MICHAEL ,  CHEN SHUANG ,  ZHANG GEOFF

IPC: C07D498/18 ,  A61K31/395 ,  A61K31/4353 ,  A61P37/06

Abstract: Una composición de análogo de rapamicina incluye una forma cristalina de un análogo de rapamicina. El cristal puede ser un hidrato, dehidrato, solvato, o desolvato. El análogo de rapamicina puede tener una estructura de la Fórmula (I), el cual es opcionalmente un profármaco, sal, derivado, o combinación de los mismos: Fórmula (I).

公开(公告)号：AU2007276837A1

公开(公告)日：2008-01-31

申请号：AU2007276837

申请日：2007-07-24

Applicant: ABBOTT LAB

Inventor： ZHANG GEOFF ,  BORCHARDT THOMAS ,  VISWANATH SHEKHAR ,  RASMUSSEN MICHAEL ,  CHEN SHUANG ,  DHAON MADHUP ,  HENRY RODGER ,  BARTELT LARRY ,  LEANNA ROBERT

IPC: C07D498/18 ,  A61K31/395 ,  A61K31/4353 ,  A61P37/06

Abstract: A process for preparing a crystalline form of a rapamycin analog, which process comprises: combining the rapamycin analog with at least one organic medium to form a mixture that is saturated with the rapamycin analog; incubating the saturated mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog from the organic medium.

公开(公告)号：DE69432611T2

公开(公告)日：2004-03-18

申请号：DE69432611

申请日：1994-09-26

Applicant: ABBOTT LAB

Inventor： STUK L ,  KERDESKY A ,  LIJEWSKI-LINCH M ,  NORBECK W ,  SCARPETTI DAVID ,  TIEN J ,  ALLEN S ,  LANGRIDGE C ,  MELCHER LAURA ,  RENO S ,  SHAM LEUNG ,  ZHAO CHEN ,  HAIGHT R ,  LEANNA ROBERT ,  MORTON E ,  ROBBINS A ,  SOWIN J

IPC: C07C213/00 ,  C07C215/28 ,  C07C225/16 ,  C07C227/18 ,  C07C229/36 ,  C07C231/12 ,  C07C233/35 ,  C07C251/40 ,  C07C255/27 ,  C07C255/42 ,  C07C269/06 ,  C07C271/20 ,  C07D209/44 ,  C07D221/14

Abstract: Processes are disclosed which are useful for the preparation of a substantially pure compound of formula (3), wherein R6 and R7 are each hydrogen or R6 and R7 are independently selected from (i), wherein Ra and Rb are independently selected from hydrogen, loweralkyl and phenyl and Rc, Rd and Re are independently selected from hydrogen, loweralkyl, trifluoromethyl, alkoxy, halo and phenyl; and (ii) wherein the naphthyl ring is unsubstituted or substituted with one, two or three substituents independently selected from loweralkyl, trifluoromethyl, alkoxy, and halo; or R6 is as defined above and R7 is R7aOC (O)- wherein R7a is loweralkyl or benzyl; or R6 and R7 taken together with the nitrogen atom to which they are bonded are (a) or (b), wherein Rf, Rg, Rh and Ri are independently selected from hydrogen, loweralkyl, alkoxy, halogen, and trifluoromethyl and R8 is hydrogen or -C(O)R'' wherein R'' is loweralkyl, alkoxy, benzyloxy or phenyl wherein the phenyl ring is unsubstituted or substituted with one, two or three substituents independently selected from loweralkyl, trifluoromethyl, alkoxy and halo; or an acid addition salt thereof.

公开(公告)号：AU2007276837B2

公开(公告)日：2013-02-07

申请号：AU2007276837

申请日：2007-07-24

Applicant: ABBOTT LAB

Inventor： LEANNA ROBERT ,  BORCHARDT THOMAS ,  VISWANATH SHEKHAR ,  CHEN SHUANG ,  BARTELT LARRY ,  RASMUSSEN MICHAEL ,  ZHANG GEOFF ,  HENRY RODGER ,  DHAON MADHUP

IPC: C07D498/18 ,  A61K31/395 ,  A61K31/4353 ,  A61P37/06

Abstract: A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate. The rapamycin analog can have a structure of Formula (I), which is optionally a prodrug, salt, derivative, or combination thereof: Formula (I)

公开(公告)号：NZ574654A

公开(公告)日：2012-03-30

申请号：NZ57465407

申请日：2007-07-24

Applicant: ABBOTT LAB

Inventor： VISWANATH SHEKHAR ,  BARTELT LARRY ,  LEANNA ROBERT ,  RASMUSSEN MICHAEL ,  DHAON MADHUP ,  HENRY RODGER ,  BORCHARDT THOMAS ,  CHEN SHUANG ,  ZHANG GEOFF

IPC: C07D498/18 ,  A61K31/395 ,  A61K31/4353 ,  A61P37/06

Abstract: Disclosed is a rapamycin analog of formula (I). Also disclosed are crystalline forms of the analogues with powder diffraction patterns as disclosed in the specification; a composition comprising a compound of formula (I); a process for preparing a crystalline form of a compound of formula (I).